Skip to content
Home/Companies/Biotech/Vera Therapeutics

Vera Therapeutics

Biotech·US·Exited 2021·Held under 1yr
Entry
2021
Hold
<1yr
Exit
2021

Who owns Vera Therapeutics?

Vera Therapeutics was owned by Abingworth through Abingworth Bioventures 8 (2021 vintage) from 2021 to 2021, exited via IPO.

Hand-verified · updated 2026-06-10

Abingworth
Investor
Abingworth
Abingworth Bioventures 8 · 2021 · Life Sciences VC

Key facts

HQUS
SectorBiotech
StatusActive
Exit Type
IPO
Buyer
–
MOIC
–
Exit Year
2021

More from Abingworth Bioventures 8

Other portfolio companies in the same fund.

Cytospire Therapeutics
Cytospire Therapeutics
Active
BiotechUK· 2026
AdvanCell
Active
BiotechAustralia· 2025
Antares Therapeutics
Active
BiotechUS· 2025
Solve Therapeutics
Active
BiotechUS· 2025
Timberlyne Therapeutics
Active
HealthcareUS· 2025
Myricx Bio
Myricx Bio
Exited 2026
BiotechUK· 2024
to

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Vera Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Vera Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue